EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

被引:2086
|
作者
Singh, A. [1 ]
Settleman, J. [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA
关键词
EMT; cancer; cancer stem cells; drug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; MIR-200; FAMILY; E-CADHERIN; LUNG-CANCER; REPRESSORS ZEB1; SMAD PROTEINS;
D O I
10.1038/onc.2010.215
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumors are cellularly and molecularly heterogeneous, with subsets of undifferentiated cancer cells exhibiting stem cell-like features (CSCs). Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. The EMT process can be regulated by a diverse array of cytokines and growth factors, such as transforming growth factor (TGF)-beta, whose activities are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in the acquisition of invasive and metastatic properties. Recent reports indicate that the emergence of CSCs occurs in part as a result of EMT, for example, through cues from tumor stromal components. Recent evidence now indicates that EMT of tumor cells not only causes increased metastasis, but also contributes to drug resistance. In this review, we will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs. We will also highlight recent studies implicating the function of TGF-beta-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal. Finally we will discuss how EMT and CSCs may contribute to drug resistance, as well as therapeutic strategies to overcome this clinically. Oncogene (2010) 29, 4741-4751; doi: 10.1038/onc.2010.215; published online 7 June 2010
引用
收藏
页码:4741 / 4751
页数:11
相关论文
共 50 条
  • [21] The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer
    Pingting Zhou
    Bo Li
    Furao Liu
    Meichao Zhang
    Qian Wang
    Yuanhua Liu
    Yuan Yao
    Dong Li
    Molecular Cancer, 16
  • [22] MSLN induced EMT, cancer stem cell traits and chemotherapy resistance of pancreatic cancer cells
    Hu, Jili
    Wang, Jia
    Guo, Xu
    Fan, Qing
    Li, Xinming
    Li, Kai
    Wang, Zhuoyin
    Liang, Shuntao
    Amin, Buhe
    Zhang, Nengwei
    Chen, Chaowen
    Zhu, Bin
    HELIYON, 2024, 10 (08)
  • [23] Cancer stem cells in drug resistance: an introduction to the e-book covering the special issue on the "Cancer Stem Cells and Drug Resistance"
    Sarkadi, Balazs
    CANCER DRUG RESISTANCE, 2023, 6 (01) : 239 - 241
  • [24] Colon cancer: Cancer stem cells markers, drug resistance and treatment
    Kozovska, Zuzana
    Gabrisova, Veronika
    Kucerova, Lucia
    BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (08) : 911 - 916
  • [25] HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil
    Korkaya, Hasan
    Wicha, Max S.
    CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1845 - 1847
  • [26] ABC Transporters, Drug Resistance, and Cancer Stem Cells
    Dean, Michael
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2009, 14 (01) : 3 - 9
  • [27] ABC Transporters, Drug Resistance, and Cancer Stem Cells
    Michael Dean
    Journal of Mammary Gland Biology and Neoplasia, 2009, 14 : 3 - 9
  • [28] The Breast Cancer Stem Cells Traits and Drug Resistance
    Zheng, Qinghui
    Zhang, Mengdi
    Zhou, Fangfang
    Zhang, Long
    Meng, Xuli
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [29] Drug Resistance Driven by Cancer Stem Cells and Their Niche
    Prieto-Vila, Marta
    Takahashi, Ryou-u
    Usuba, Wataru
    Kohama, Isaku
    Ochiya, Takahiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [30] Cancer stem cells and drug resistance: the potential of nanomedicine
    Vinogradov, Serguei
    Wei, Xin
    NANOMEDICINE, 2012, 7 (04) : 597 - 615